Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when CLNN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsClene prices $7M stock offering to fund NDA filing and Phase 3 trial for lead drug
Filed May 5, 2026 · Period ending May 5, 2026 · ~1 min read
Key Changes
-
high
Clene is selling 1 million shares at $7.00 per share through Canaccord Genuity, raising approximately $6.4 million net after fees. Proceeds will fund the NDA filing for CNM-Au8, Phase 3 clinical trials, manufacturing expansion, and early-stage R&D.
Item 1.01 verify on EDGAR → -
high
The offering dilutes existing shareholders by approximately 1 million shares. Underwriting fees are 6.5% of gross proceeds plus $140,000 in other expenses, totaling roughly in transaction costs.
Item 1.01 verify on EDGAR → -
medium
Company insiders, officers, and directors agreed to a 60-day lock-up preventing them from selling shares without underwriter consent. This restriction helps stabilize the stock price post-offering but expires in early July 2026.
Item 1.01 verify on EDGAR → -
low
The offering is expected to close May 6, 2026, subject to customary closing conditions. Legal opinion from Dorsey & Whitney confirms validity of the shares being issued.
Item 1.01 verify on EDGAR →
Summary
Clene Inc. priced an underwritten public offering of 1 million common shares at $7.00 per share, raising approximately $6.4 million after fees. The biotech company plans to use proceeds primarily for filing a new drug application for its lead candidate CNM-Au8, conducting Phase 3 clinical trials, and expanding manufacturing capacity.
This capital raise comes as the company advances its lead asset toward potential commercialization. For retail investors, this offering represents immediate dilution of roughly 1 million shares at a fixed price of $7.00. The relatively modest raise of $6.4 million net suggests the company is funding near-term regulatory and clinical milestones rather than long-term operations.
The 60-day insider lock-up provides some short-term price stability but is notably brief compared to typical 90-180 day restrictions. Watch for the NDA filing timeline and Phase 3 trial enrollment updates in coming quarters, as these milestones will determine whether this capital was sufficient or if additional dilutive financing will be needed before potential product approval and revenue generation.
Section-by-Section Diff
Event · Item 9.01 — Financial Statements and Exhibits
Clene Inc. entered into an underwriting agreement with Canaccord Genuity LLC on May 5, 2026, indicating a securities offering.
Added in current filing · verify on EDGAR →
Underwriting Agreement, dated May 5, 2026, by and between Clene Inc. and Canaccord Genuity LLC.
Clene Inc. executed an underwriting agreement with Canaccord Genuity LLC on May 5, 2026. This typically indicates the company is conducting a public securities offering, such as issuing new shares or other securities to raise capital. The specific terms, size, and pricing of the offering are not disclosed in this 8-K filing itself.
Added in current filing · verify on EDGAR →
Opinion of Dorsey & Whitney LLP.
The company filed a legal opinion from Dorsey & Whitney LLP, which is standard practice in securities offerings to confirm the validity of the securities being issued. This supports the interpretation that a capital raise transaction is occurring.
Added in current filing · verify on EDGAR →
Press release, dated May 5, 2026.
A press release dated May 5, 2026 was filed as an exhibit. While the content is not provided in this 8-K body, press releases accompanying underwriting agreements typically announce the offering details, including size, use of proceeds, and pricing terms.
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
The Company estimates the net proceeds from the offering will be approximately $6.4 million, after deducting estimated underwriting discounts and commissions and other offering expenses payable by the Company. The Company will pay discounts and commissions equal to 6.5% of the aggregate gross proceeds from the offering and the Company estimates it will incur approximately $140,000 of other offering expenses. The ... Company expects to use the net proceeds from the offering, together with its existing cash, for expenses primarily related to general corporate purposes, as well as to fund the following: the preparation and filing of the Company’s new drug application for its lead drug candidate, CNM-Au8; the conduct of and continued access to CNM-Au8 in the Company’s ongoing expanded access protocols and future confirmatory Phase 3 clinical trial; manufacturing expansion; potential future commercialization efforts; and for additional early-stage research and development activities.
The company expects to receive approximately $6.4 million in net proceeds after paying 6.5% in underwriting fees and $140,000 in other expenses. The funds will be used for filing a new drug application for CNM-Au8, conducting Phase 3 clinical trials, manufacturing expansion, commercialization efforts, and early-stage R&D activities.
Added in current filing · verify on EDGAR →
Pursuant to certain ‘‘lock-up’’ agreements (the “Lock-Up Agreements”), for a period of 60 days after the date of the Underwriting Agreement, the Company, certain of its executive officers, directors and certain affiliated entities of the Company’s directors have agreed, subject to certain exceptions, not to (i) directly or indirectly, sell, offer to sell, contract to sell or lend, effect any short sale or establish or increase a Put Equivalent Position (as defined in Rule 16a-1(h) under the Exchange Act) or liquidate or decrease any Call Equivalent Position (as defined in Rule 16a-1(b) under the Exchange Act), pledge, hypothecate or grant any security interest in, or in any other way transfer or dispose of, any of the Company’s common stock or any securities convertible into or exchangeable or exercisable into the Company’s common stock (collectively, the “Lock-Up Securities”), (ii) make any demand for, or exercise any right with respect to the registration of any of the Lock-Up Securities, or the filing of any registration statement, prospectus or prospectus supplement (or an amendment or supplement thereto) in connection therewith, (iii) enter into any swap, hedge or other agreement or any transaction that transfers, in whole or in part, the economic consequence of ownership of the Lock-Up Securities, whether any such swap or transaction is to be settled by delivery of the Company’s common stock or other securities, in cash or otherwise, or (iv) publicly announce the intention to do any of the foregoing, without the prior written consent of Canaccord Genuity LLC.
The company, its executive officers, directors, and certain affiliated entities agreed to a 60-day lock-up period during which they cannot sell, transfer, or otherwise dispose of company common stock or related securities without the underwriter's consent. This restriction helps stabilize the stock price following the offering.
Event · Item 8.01 — Other Events
Clene announced an offering via press release on May 5, 2026.
Added in current filing · verify on EDGAR →
On May 5, 2026, the Company issued a press release announcing the offering.
Clene disclosed that it issued a press release on May 5, 2026 announcing an offering. The 8-K does not provide details about the type, size, or terms of the offering; those details would be in the referenced press release exhibit.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify